Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Webinar to be held
Webinar to include presentations by Daré management and key opinion leaders in reproductive and sexual medicine
Sheryl A. Kingsberg, PhD, Division Chief of Behavioral Medicine, Department of OBGYN, University Hospitals Cleveland Medical Center, Ohio, and Past President of The International Society for the Study of Women's Sexual Health(ISSWSH), as well as Past President of The North American Menopause Society(NAMS), and James A. Simon. M.D., CCD, NCMP, IF, FACOG, Clinical Professor, Obstetrics and Gynecology, George Washington Universityand President and Medical Director of IntimMedicine Specialists®, as well as Past President of each of NAMS and ISSWSH.
A link to access the live webinar will be available under “Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Following the conclusion of the live event, a replay will be available under “Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com until
About FSAD and Sildenafil Cream, 3.6%
FSAD is a condition characterized primarily by a persistent or recurrent inability to attain or maintain sufficient genital arousal (an adequate lubrication-swelling response) during sexual activity, frequently resulting in distress or interpersonal difficulty, and, of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction (ED) in men. As with ED in men, FSAD is associated with insufficient blood flow to the genitalia.
Sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra® for the treatment of ED in men. Sildenafil Cream, 3.6% (Sildenafil Cream) is an investigational, proprietary cream formulation of sildenafil designed for topical administration to the vulvar-vaginal tissue to increase genital blood flow and provide improvements in the female genital arousal response, while avoiding systemic side effects observed with oral formulations of sildenafil. If development is successful, Sildenafil Cream has the potential to be the first FDA-approved pharmacologic treatment for FSAD.
Market research suggests that 16% of women in the
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility.
Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose
Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com),
Media on behalf of Daré
Source: Daré Bioscience, Inc.